Kosair Charities Pediatric Clinical Research Unit, 2013
Sullivan, Janice E.
• NIH Grant Reviewer
• Chair of Executive Committee, Section on Clinical Pharmacology & Therapeutics (American Academy of Pediatrics)
• Member, Committee on Drugs (American Academy of Pediatrics)
• Member, Section of Pediatric Resident Education Committee (Society of Critical Care Medicine)
• Committee Member, SCCM Task Force for Sedation & Analgesia during Pediatric Mechanical Ventilation Guidelines (Society of Critical Care Medicine)
• Member, Section of Pediatric Resident Education Committee (Society of Critical Care Medicine)
Brothers, Kyle B.
• Member, Workgroup for Consent, Education, Regulation, and Consultation, (Electronic Medical Records and Genomics Consortium)
• Member, Workgroup for Actionable Variants, (Electronic Medical Records and Genomics Consortium)
• Member, Pediatric Workgroup, (Clinical Sequencing Exploratory Research Consortium)
• Member, Actionable Results/Return of Results Workgroup, (Clinical Sequencing Exploratory Research Consortium)
• Member, Outcomes and Measures Workgroup, (Clinical Sequencing Exploratory Research Consortium)
• Member, Qualitative Measures Workgroup, (Clinical Sequencing Exploratory Research Consortium)
Smith MJ, Condurache CT, Sullivan JE. “Safety and Pharmacokinetics of Multiple Dose Intravenous and Oral Clindamycin in Pediatric Subjects with BMI > 85th Percentile”, The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). HSPPO #13.0182.
Wintergerst KA, Berkenbosch JW, Sullivan JE. “Coagulation and Fibrinolysis in a Pediatric Insulin Titration Trial”, National Institute of Health. Subcontract with the University of California San Francisco. HSPPO #13.0389, $10,000.
Wintergerst KA, Berkenbosch JW, Sullivan JE. “Heart and Lung Failure – Pediatric Insulin Titration Trial (HALF-PINT), National Institute of Health. Subcontract with Harvard Medical School. HSPPO #13.0245, $205,000.
Brothers KB, Myers JA, Rothstein MA. “Genomic Diagnosis in Children with Developmental Delay”, National Institutes of Health. Subcontract with HudsonAlpha Institute for Biotechnology. HSPPO #IAA-45, $534,796.
Brothers KB. “Patient Perspectives on Broad Consent in Biobank Research in the eMERGE Network”, National Institutes of Health. Subcontract with Vanderbilt University. $20,121.
Brothers KB. “Patient Perspectives on Broad Consent in Biobank Research in the eMERGE Network (eMERGE Coordinating Center)”, National Institutes of Health. Subcontract with Vanderbilt University. $18,913.
Logsdon MC, Myers JA, Josephson AM, Davis DW, Brothers KB. “Social Media, Teen Moms, and PPD”, National Institutes of Health, $449,943.
Schmidt KM, Sullivan JE, Condurache CT. “Improved Understanding of the Biology and Use of TNF Inhibition in Children with JIA.” National Institute of Health. Subcontract with Cincinnati Children’s Hospital Medical Center. HSPPO #12.0005. $11,000.
Radmacher PG, Sullivan JE, Adamkin DH. “The Neonatal and Necrotizing Enterocolitis.” National Institute of Health. Subcontract with Washington University School of Medicine. HSPPO #11.0136. $72,064 (yr 1); $315,000 (yr 2); $315,000 (yr 3).
Porter MB, Sullivan JE, Berkenbosch JW, Calhoun AW, Montgomery VL, Ruppe MD, Padmanabhan P, McDonald MJ, Orman K, Potter KE, Hardin AO, Sears LL. “Therapeutic Hypothermia After Pediatric Cardiac Arrest: The THAPCA Trials.” National Institute of Health. Subcontract with the University of Michigan. HSPPO #10.0464. $47,423.
Montgomery VL, Sullivan JE. “Observation of Multi-center Quality Improvement Project: Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs.” National Institute of Health. Subcontract with Children’s Hospital of Philadelphia. HSPPO #10.0238. $2,090.
Sullivan, JE, Condurache CT, Berkenbosch JW. “Identification of New Mechanistic of Adverse Response to Acetaminophen.” Subcontract ACH-NIH. HSPPO #09.0558. $3,000 (Yr1), $12,632 (Yr 2), $12,633 (Yr 3), $25,995 (Yr 4).
Montgomery VL, Sullivan JE, Condurache CT. “Genetic Epidemiology and Immune Response to Life-threatening Influenza Infection in Children and Young Adults.” PALISI Network/NIH. HSPPO #09.0641. Award # 1RO1AI08401101A1. $12,150.
Montgomery VL, Sullivan JE, Condurache CT. “Epidemiology and Immune Response to Life-Threatening Influenza in Children and Young Adults.” NIH. Subcontract with Children’s Hospital Boston. HSPPO# 09.0641. $6,000.
Sullivan JE (PI). “Goal-directed Resuscitative Interventions during Pediatric Inter-facility Transport.” National Institute of Health (subcontract Arkansas Children’s Hospital Research Institute). #1R21HD060171-01A2. $22,098.
CONTRACTS / ONGOING RESEARCH
Raj A, Condurache CT, Sullivan JE. “A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A”, Baxter Healthcare Corporation. Phase 2/3, HSPPO #PENDING.
Kenagy DN, Condurache CT, Gupta S, Sullivan JE. “A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 with Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis”, AbbVie. Phase III, HSPPO #PENDING.
Raj A, Condurache CT, Sullivan JE. “A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises. (SUSTAIN)”, Selexys Pharmaceuticals Corporation. Phase II, HSPPO #PENDING.
Raj A, Condurache CT, Sullivan JE. “A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease”, Eli Lilly and Company. Phase III, HSPPO #13.0439.
Schikler KN, Sullivan JE, Condurache CT, Schmidt KM. “A phase IIa, International, Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety and Pharmacokinetics of 4 x 375 mg/m2 Intravenous Rituximab in Pediatric Patients with Severe Granulomatosis with Polyangiitis (Wegener’s) or Microscopic Polyangiitis.” Roche. Phase 2, HSPPO #PENDING.
Sullivan JE, Condurache CT, Espinosa C, Smith MJ. “A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months To 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections”, Durata Therapeutics, Inc.. Phase I, HSPPO #13.0375.
Goodin KM, Gowans GC, Sullivan JE, Condurache CT. “A Phase 3, Open-Label, Randomized, Multi-Center Study to Assess the Safety and Tolerability of an Induction, Titration, and Maintenance Dose Regimen of BMN 165 Self-Administered by Adults with Phenylketonuria Not Previously Treated with BMN 165”, BioMarin Pharmaceuticals Inc. Phase III, HSPPO #13.0311.
Goodin KM, Gowans GC, Sullivan JE, Condurache CT. “A Three-Part, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Four-Arm, Discontinuation Study to Evaluate the Efficacy and Safety of Subcutaneous Injections of BMN 165 Self-Administered by Adults With Phenylketonuria”, BioMarin Pharmaceuticals Inc. Phase III, HSPPO #13.0394.
Raj, A, Condurache CT, Sullivan JE. "Evaluation Of Purified Poloxamer 188 In Children In Crisis (Epic): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Of Anx-188 (Purified Poloxamer 188) Injection In Children With Sickle Cell Disease Experiencing Vasoocclusive Crisis”, Adventrx Pharmaceuticals, Inc. Phase III, HSPPO #13.0300.
Wintergerst KA, Sullivan JE, Foster MB, Condurache CT. “A Phase III, Multicenter, Double-Blind, Randomized, Placebo and Metformin-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control”, Merck Sharp & Dohme Corp., Protocol 083-01. Phase III, HSPPO #13.0287, $206,904.
Schikler KN, Schmidt KM, Sullivan JE. “Pediatric Vasculitis Initiative (PedVas) Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes”, Canadian Institutes of Health Research (CIHR). HSPPO #13.0268.
O’Hagan, A, Sullivan, JE, Condurache CT. “A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor Monotherapy and in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F50.” Vertex. Phase 3, HSPPO #13.0257.
Sullivan JE, Condurache CT, Espinosa CM. “A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection”, AstraZeneca. Phase I, HSPPO #13.0243.
O’Hagan AR, Morton RL, Sullivan JE. “An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis”, Vertex Pharmaceutical Incorporated. HSPPO #13.0238.
Gowans GC, Condurache CT, Sullivan JE, Goodin KM. “A Multicenter, Open-label BMN 110 US Expanded Access Program (BMN 110 US EAP) to Provide BMN 110 to Patients Diagnosed with MPS IVA”, BioMarin Pharmaceutical Inc. HSPPO #13.0210.
Wintergerst KA, Sullivan JE, Foster MB, Condurache CT. “A Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Release Metformin) in Pediatric Subjects with Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy”, Merck Sharp & Dohme Corp., Protocol 289-00. Phase III, HSPPO #13.0186, $134,454.
Goodin KM, Sullivan JE, Asamoah A, Gowans GC, Raj AB, Leahy RA, Condurache CT, Hersh JH, Keller BB, Cheerva AC. “A Phase 4, Open-Label, Prospective Study in Patients with Pompe Disease to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale.” Genzyme. Phase 4, HSPPO #13.0088.
Craft LT, Sullivan JE. “The Fragile X Clinical and Research Consortium (FXCRC) FORWARD Registry and Database.” National Fragile X Foundation. HSPPO #13.0046.
OTHER FUNDED STUDIES:
Condurache CT, Sullivan JE, Eid NS. “Effects of Educational Intervention on Long Term Outcomes of Hospitalized Children with Asthma.” Passport Health Plan 955 (iHOP, Improving Health Outcomes Program). $50,000.
Montgomery VL, Sullivan, JE, Condurache CT. “Influenza Vaccine Effectiveness in High-risk Children.” PALISI Network/CDC. $99,900.
Williams PG, Sullivan JE, Sears LL, Casanova MF. “Double-Blind, Placebo-Controlled, Crossover Study of Glutathione Vitamin C and Cysteine in Children with Autism and Severe Behavior Problems.” Children’s Hospital Foundation. $49,999.
Jeffries A, Stewart DL, Stutts J, Condurache CT, Sullivan JE. A Multi-Center, Open-Label, Single-Dose Pharmacokinetic Study of Intravenous Pantoprazole in Preterm Infants and Infants 0-11 Months with a Clinical Diagnosis of Gastroesophageal Reflux Disease (GERD) or the need for Acid Suppression. Wyeth Investigator Grant Award (now Pfizer), HSPPO #08.0372. $195,000.
Wintergerst KA, Sullivan JE, Berkenbosch JW, Montgomery VL. “Hyperglycemic control in critically ill children.” Investigator Initiated QA. Protocol N/A. Phase N/A. HSPPO #09.0529.
Calhoun A, Sullivan JE, Stewart DL, Stephen T. “Omegaven Treatment for PN Associated Liver Disease in Children: A Longitudinal Study.” (IND 69,208) HSPPO # 07.0117.
Sullivan JE (PI),Rabalais GP. “Kosair Charities Pediatric Clinical Research Unit.” Kosair Charities. Grant #712H (2013-2014). $125,000.
Sullivan JE (PI), Rabalais GP. “Kosair Charities Pediatric Clinical Research Unit.” Kosair Charities. Grant #712H (2012-2013). $175,000.
Annual Pediatric Clinical Pharmacology Conference: The KCPCRU hosts a clinical pharmacology conference annually. In 2013, Dr. John Bradley presented Grand Rounds “New Antibiotics for Children: Why We Don’t Have Any (And How That is Now Changing)” followed by three additional local speakers who focused on different aspects of antimicrobial therapy for the remainder of the ½ day conference. The conference audience included physicians, pharmacists, nurses and students. Ongoing education in pediatric clinical pharmacology is critical to keep those caring for children well informed on pharmacological issues.
Antimicrobial Stewardship Task Force (Sullivan JE): Members of this multidisciplinary group (reports to the Pharmacy & Therapuetics Committee) established to develop programs to enhance the appropriate selection, dosing, route and duration of antimicrobial therapy, in order to optimize clinical outcomes but minimize toxicity, emergence of pathogenic organisms, and development of resistance.
Pharmacy & Therapeutics Committee (Sullivan JE, Chair): This committee serves in an advisory capacity to the Medical Staff and Kosair Children’s Hospital Administration in all matters pertaining to the use of drugs, including investigational drugs. It also maintains an updated formulary of drugs accepted for use in the hospital, reviews adverse events/medication errors, and provides suitable educational programs for the hospital's professional staff on matters relating to drug use.
Sedation Committee (Sullivan JE): This multidisciplinary committee serves in an advisory capacity to the Medical Staff and Kosair Children’s Hospital Administration in all matters pertaining to inpatient and outpatient sedation. Quality control and ongoing review of sedation procedures provides for improvements for clinical service and education in sedation.
Medication Safety Committee: This multidisciplinary committee serves in an advisory capacity to the Medical Staff and Kosair Children’s Hospital Administration in all matters pertaining to medication practices and safety.
Hospital Ethics Committee (Brothers KB): This multidisciplinary committee addresses clinical and institutional ethics issues for Kosair Children’s Hospital, including providing clinical ethics consultation service for inpatient units. The committee also addresses educational needs related to ethics issues for Kosair Children’s Hospital, including planning the annual Pediatrics Bioethics Day. This committee also advises the Norton Healthcare Ethics Council on pediatric policy issues relevant to the hospital system.
NATIONAL/INTERNATIONAL ORAL AND POSTER PRESENTATIONS:
Valentine K, Lieh-Lai M, Sullivan JE, Blumer J. Pharmacokinetics of Terbutaline in Critically Ill Children with Asthma Admitted to the Pediatric Intensive Care Unit. Detroit, MI. November 2012
Brothers KB, Westbrook MJ, Wright MF, Van Driest SL, McGregor TL, Denny JC, Zuvich RL, Clayton. “Mapping the Incidentalome: QuantifYing Incidental Findings Generated Through a Clinical”, American Society for Human Genetics. San Francisco, California. November 2012.
Rigby MR, Leong T, Sullivan JE, Rotta A, Nitu M, Wintergerst KA. De Novo Adoption of a Hyperglycemic Protocol by 2 Pediatric Intensive Care Units. Pediatric Critical Care Colloquium Meeting. Santa Monica, CA. September 2012.
James LP, Sullivan JE, Letzig L, Abdul-Rahman S, Capparelli E, Yan K, Simpson PM, Roberts DR. “Acetaminophen Protein Adducts in Hospitalized Children Receiving Acetaminophen.” American Society for Clinical Pharmacology & Therapeutics Annual Meeting. National Harbor, Maryland. March 12-17, 2012.
Anderson J, Mayes S, Owen E, Sullivan JE. "Safety of Endotracheal Lidocaine in Critically Ill Children." American Society of Health-System Pharmacist – Annual Conference. December 2012.
Wright MF, Clayton EW, Pulley J, Brothers KB. “Patient Perspectives on the PREDICT Program : Focus Groups on Practical Issues in the Design of a Clinical”, 2011 Congress of the Ethical, Legal and Social Implications Research Program. Chapel Hill, North Carolina. April 2011.
Brothers, KB. “Working with Vaccine-Hesitant Parents Urbana”, CME Presentation - Carle Foundation Hospital - Bioethics Seminar Series. Illinois. September 2013.
Brothers, KB. “Human Non-Subjects Biobanking: Privacy, Perspectives, and Personalized Medicine for Everyone”, Why We Can’t Wait: Conference to Eliminate Health Disparities in Genomic Medicine. San Francisco, California. May 2013.
Brothers, KB. “The Genome on the Exam Table: Clinical Applications of Whole Genome Sequencing”, Center for Genetics and Molecular Medicine Symposium - Whole Genome Sequencing: From Lab to Clinic. Louisville, Kentucky. November 2012.
Sullivan, JE. “Making Life Better for Children.” Invited Speaker at the Kosair Charities W. Barnett Owen Society Luncheon. Louisville, KY. October 19, 2012.
Sullivan, JE. Lorazepam Trial: Challenges of Pediatric Sedation Scores. Clinical Development Programs for Sedation Products: Public Workshop. FDA Sedation Workshop for Center for Drug Evaluation and Research. Silver Springs, MD. May 3, 2012.
Brothers, KB. “Issues of Consent and Return of Results in Genomics Research with Children”, St. Jude Children’s Research Hospital Clinical Research Mini-Symposium - Genomics, Research and Children: Regulations, Ethics and Community. Memphis, Tennessee. August 2012.
Brothers KB, Van Driest SL. “BioVU: Using Biorepositories to Answer Research Questions”, State of the Art Presentation, CTSA Consortium Child Health Oversight Committee. Boston, Massachusetts. April 2012.
Sullivan, JE. “Case Presentations and Panel Discussion.” Moderator; Pediatric Pharmacology Symposium. Louisville, Kentucky. March 30, 2012.
Sullivan JE, Keefe D, Zhou Y, Satlin L, Fang H, Yan J. Pharmacokinetics, safety profile, and efficacy of aliskiren in pediatric patients with hypertension. Clinical Pediatrics [serial online]. July 2013;52(7):599-607.
Wessel D, Berger F, Newburger J, et al. Clopidogrel in infants with systemic-to-pulmonary-artery shunts. The New England Journal of Medicine [serial online]. June 20, 2013;368(25):2377-2384.
Sanders R; Giuliano J; Sullivan JE; Brown C; Walls R; Nadkarni V; Nishisaki A. Level of trainee and tracheal intubation outcomes. Pediatrics 2013;131:e821–e828.
Nishisaki A, Turner DA, Brown CA, et al. (Sullivan JE was a participating investigator). A National Emergency Airway Registry for Children (NEAR4KIDS) landscape of tracheal intubation in 15 pediatric intensive care units. Crit Care Med 2013; 41:874–885.
Rosenbloom ST, Madison JL, Brothers KB, Bowton EA, Clayton EW, Malin BA, Roden DM, Pulley J. Ethical and Practical Challenges to Studying Patients Who Opt Out of Large-Scale Biorepository Research. Journal of the American Medical Informatics Association. 2013.
Webster THG, Beal SJ, Brothers KB. Motivation in the Age of Genomics: Why Incidental Genetic Findings of Disease Susceptibility Might Not Motivate Behavior Change. Life Sciences, Society, and Policy. 2013; 9 (8).
Michalczyk K, Sullivan JE, Berkenbosch JW. Pretreatment with midazolam blunts the rise in intracranial pressure associated with ketamine sedation for lumbar puncture in children. Pediatr Crit Care Med 2013; 14:e149–e155.
Wells T, Blowey D, Sullivan JE, Blumer J, et al. Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension. Paediatr Drugs. 14(6):401-409, 2012. 2012 Aug 13. doi: 10.2165/11631450-000000000-00000.
Brothers KB, Westbrook MJ, Wright MF, Myers JA, Morrison DR, Madison JL, Pulley JM, Clayton EW. Patient Awareness and Approval for an Opt-Out Genomic Biorepository. Personalized Medicine. 2013; 10 (4): 349-359.
McGregor TL, Van Driest SL, Brothers KB, Bowton EA, Muglia LJ, Roden DM. Inclusion of pediatric samples in an opt-out biorepository linking DNA to de-identified medical records: Pediatric BioVU. Clinical Pharmacology & Therapeutics. 2013; 93 (2): 204-211.
Redwine K, Howard L, Simpson P, Li SH, Yan K, James L, Blumer J, Sullivan J, Ward R, Wells T; Network of Pediatric Pharmacology Research Units Effect of placebo on ambulatory blood pressure monitoring in children. Pediatr Nephrol. (10):1937-42, 2012. Epub 2012 May 24.
Cohen-Wolkowiez M, Poindexter B, Bidegain M, Weitkamp JH, Schelonka RL, Randolph DA, Ward RM, Wade K, Valencia G, Burchfield D, Arrieta A, Mehta V, Walsh M, Kantak A, Rasmussen M, Sullivan JE, Finer N, Rich W, Brozanski BS, van den Anker J, Blumer J, Laughon M, Watt KM, Kearns GL, Capparelli EV, Martz K, Berezny K, Benjamin DK Jr, Smith PB; for the Meropenem Study Team. Safety and Effectiveness of Meropenem in Infants With Suspected or Complicated Intra-abdominal Infections. Clin Infect Dis. 2012 Sep 21. (EPUB)
Cohen-Wolkowiez M, Ouellet D, Smith PB, James L, Ross A, Sullivan JE, et al. Population pharmacokinetics of metronidazole using scavenged samples from preterm infants. Antimicrobial Agents and Chemotherapy. 56(4):1828-37, 2012.
Cohen-Wolkowiez M, Benjamin DK Jr, Ross A, James LP, Sullivan JE, Walsh MC, Zadell A, Newman N, White NR, Kashuba AD, Ouellet D. Population pharmacokinetics of piperacillin using scavenged samples from preterm infants. Ther Drug Monit. 2012 Jun;34(3):312-9.
Sandstrom M, Davidson G, Tolia V, Sullivan JE, Langstrom G, Lundborg P, Brown K. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprozole in children aged 0 to 17 years. Clin Ther. 34:1828-1838, 2012.
Wintergerst KA, Foster MB, Sullivan JE, Woods CR: Association of hyperglycemia, glucocorticoids, and insulin use with morbidity and mortality in the pediatric intensive care unit. Journal of Diabetes Science and Technology. 6(1): 5-14, 2012.
Fullerton SM, WolfWA , Brothers KB, Clayton EW, Crawford DC, Denny JC, Greenland P, Koenig BA, Leppig KA, Lindor NM, McCarty CA, McGuire AL, McPeek Hinz ER, Mire! DB, Ramos EM, Ritchie MD, Smith ME, Waudby CJ, Burke W, Jarvik GP. Return ofindividual Research Results from Genome-wide Association Studies: Experience of the Electronic Medical Records and Genomics (eMERGE) Network . Genetics in Medicine . 2012; 14 (4): 424-431.
Brothers KB, Clayton EW . Parental Perspectives on a Pediatric Human Non-Subjects Biobank. American Journal of Bioethics: Primary Research. 2012; 3 (3): 21-29.
Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, Delaney JT, Bowton E, Brothers KB, Johnson K, Crawford DC, Schildcrout J, Masys DR, Dilks H, Clayton EW, SchultzE, Laposata M, McPherson J, Jirjis JN, Roden DM. Operational implementation of prospective genotyping for personalized medicine: The design of the Vanderbilt PREDICT project. Clinical Pharmacology & Therapeutics. 2012; 92 (I): 87-95.
McGregor TL, Van Driest SL, Brothers KB, Bowton EA, Muglia LJ, Roden DM. Inclusion of pediatric samples in an opt-out biorepository linking DNA to de-identified medical records: Pediatric BioVU . Clinical Pharmacology & Therapeutics. 2012.
Westbrook MJ, Wright MF, Van Driest SL, McGregor TL, Denny JC, Zuvich RL, Clayton EW, Brothers KB. Mapping the Incidentalome: Estimating Incidental Findings Generated Through Clinical Pharmacogenomics Testing . Genetics in Medicine. 2012; 15 (5): 325-331.
Langanke M, Fischer T, Brothers KB. Public Health - It is running through my veins: Personalized Medicine and Individual Responsibility for Health. Individualized Medicine. 2012: 165- 188.